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Abstract
Background & Aims—Patients with inflammatory bowel disease (IBD) might be at increased risk
for certain malignancies. We evaluated the risk of non-melanoma skin cancer (NMSC) in patients
with IBD and determined how immunosuppressive and biologic medications affect this risk.
Methods—We performed retrospective cohort and nested case-control studies using administrative
data from PharMetrics Patient Centric Database. In the cohort study, 26403 patients with Crohn’s
disease (CD) and 26974 patients with ulcerative colitis (UC) were each matched to 3 non-IBD
controls. NMSC risk was evaluated by incidence rate ratio. In the nested case-control study, 387 CD
patients and 355 UC patients with NMSC were each matched to 4 IBD patients without NMSC using
incidence density sampling. Conditional logistic regression was used to determine the association
between specific IBD medication use and NMSC.
Results—In the cohort study, the incidence of NMSC was higher among patients with IBD
compared to controls (incidence rate ratio [IRR] 1.64, 95% confidence interval [CI] 1.51–1.78). In
the nested-case control study, recent thiopurine use (≤90 days) was associated with NMSC (adjusted
odds ratio [OR] 3.56, 95% CI 2.81–4.50), as was recent biologic use among patients with CD
(adjusted OR 2.07, 95% CI 1.28–3.33). Persistent thiopurine use (>365 days) was associated with
NMSC (adjusted OR 4.27, 95% CI 3.08–5.92), as was persistent biologic use among patients with
CD (adjusted OR 2.18 95% CI 1.07–4.46).
Conclusions—Patients with IBD, especially those that receive thiopurines, are at risk for NMSC.
Appropriate counseling and monitoring of such patients with IBD is recommended.
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Introduction
One in five Americans develops skin cancer, which accounts for one third of all cancers in the
United States.1 In fact, non-melanoma skin cancer (NMSC) is one of the most common types
of cancer in lighter skin type populations. There were over a million cases of NMSC diagnosed
in 2008. The causes of NMSC are multifactorial, including both environmental and host factors.
Known environmental risk factors for NMSC include sun exposure (ultraviolet (UV) light),
chemical exposures and ozone depletion. Host risk factors include human papilloma virus,
genetic susceptibilities, skin tone and immunosuppression.2 NMSC incidence increases with
decreasing latitude, thereby demonstrating the profound risk of sun exposure.3
Patients with inflammatory bowel disease (IBD) may be at increased risk for NMSC, either
related to the immunosuppressive medications used to treat the disease and/or underlying
altered regulation of the immune system. In studies of patients post organ transplant on
immunosuppressive medications, there is a markedly increased risk of SCC that correlates with
degree of immunosuppression.4–6 For this reason, routine skin examination is performed in
post-transplant populations. Fewer studies have focused on NMSC risk in patients with IBD
who use immunosuppressive medications,7–9 and guidelines for skin cancer screening and
prevention are not included in current practice guidelines for IBD.
The specific aims of this study were 1) to evaluate the risk of NMSC in patients with and
without IBD and 2) to evaluate the risk of NMSC in patients with IBD who use
immunosuppressive medications or biologic anti-tumor necrosis factor (anti-TNF) therapies
as compared to IBD patients who do not use these medications.
Materials and Methods
Data Source
We analyzed the procedural and outpatient pharmaceutical insurance claims contained in the
PharMetrics Patient-Centric Database (IMS Health, Watertown, MA) for the period August 1,
1996 through June 30, 2005. This longitudinal, patient-level database has been used in previous
epidemiological studies of IBD.10, 11 The included plans capture a geographically diverse
sample. The number of plans per major U.S. census region (East, South, Midwest, West) ranges
from 12–34 and the number of states represented per region ranges from 5–10. The database
contains information on over 9 million enrollees, with anywhere from 19,000 to 3.6 million
(mean, 992,000) enrollees per state. At the time of this study, the database included claims
from 87 health plans in 33 states. Prior studies have reported PharMetrics to be representative
of the national commercially-insured population on a variety of demographic measures,
including geographic region, age, gender, and health plan type.12
Study Design
We performed a retrospective cohort study to determine the overall risk of NMSC in IBD
patients compared to non-IBD controls, and a nested-case control to determine the independent
effects of medication use (immunosuppressive and anti-TNF therapy) on NMSC among
patients with IBD. A similar design has previously been used by Gupta et al to evaluate the
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incidence of herpes zoster in patients with IBD and the effects of various medication exposures.
13
Cohort Study
Patient selection—All patients aged <64 with at least 6 months of continuous health plan
enrollment were eligible for inclusion in this analysis. We chose 64 as the upper age limit to
avoid the possibility of missing data resulting from Medicare dual eligibility (which begins at
age 65). We identified cases of Crohn’s disease (CD) and ulcerative colitis (UC) using a
previously reported administrative definition.10 This definition included patients with at least
3 health care contacts, on different days, associated with an International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9) diagnosis code for CD (555.xx) or UC
(556.xx), or patients with at least one claim for CD or UC and at least 1 pharmacy claim for
any of the following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-
mercaptopurine, azathioprine, infliximab, adalimumab, and enteral budesonide. For patients
who had claims for both CD and UC, disease assignment was made according to the majority
of the last 9 claims, or the majority of total claims if there were fewer than 9.
We matched each IBD patient to 3 control subjects by age, gender, U.S. census region, and
length of enrollment. Region of the country was defined by standard regional definitions from
the United States Census Bureau. The outcome of NMSC was only assessed after at least 3
months of exposure time within the cohort to minimize the inclusion of prevalent cases.
Assessment of outcome (non melanoma skin cancer)—The primary outcome of
interest was first diagnosis of NMSC identified by either 1) a claim containing a Current
Procedural Terminology, 4th edition (CPT-4) code for interpretation of pathology from an
office or surgical setting (88301-88309 and/or 88329-88332) and an International
Classification of Diseases, 9th revision (ICD-9) diagnosis code of NMSC (173.0–173.9 or
232.0–232.9), or 2) a claim containing a CPT-4 code for for destruction or excision (116xx,
172xx, 17300-17310) and one of the previously mentioned ICD-9 codes of NMSC. Pathology
CPT codes and ICD-9 diagnosis codes were used to identify cases of NMSC in a previous
epidemiological study of administrative data.14
Assessment of follow-up time interval—For each IBD patient, the follow up period
began with the 1st claim with a diagnosis code defining CD or UC. For controls, follow up
began on the first day of health plan eligibility. Follow up continued until whichever of the
following occurred first: diagnosis of NMSC, death, discontinuation of insurance coverage or
age >65.
Statistical Analysis—We used descriptive statistics to summarize characteristics of cases
and controls. Continuous variables are reported as mean +/− standard deviation (SD) and
categorical variables are reported as percentages. We then calculated incidence rates of NMSC
(per 100,000 person-years) and used incidence rate ratios (IRRs) and 95% confidence intervals
to compare the incidence of NMSC in IBD patients and controls. We also performed subsequent
analyses, stratifying by region of the country (defined by United States census groups), age (in
decades), and disease type (UC versus CD).
Nested Case-Control Study
We next conducted a case-control study evaluating the association between
immunosuppressive or biologic anti-TNF medication use and NMSC. This study was nested
within the previously defined cohort of patients with IBD.
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Selection of Cases and Controls—Cases were those IBD patients who were diagnosed
with NMSC and controls were those IBD patients without NMSC. Each case patient was
matched on gender, age, geographic region, disease type (CD or UC) and duration of follow-
up to 4 IBD patients who did not have NMSC using incidence density sampling.15 In this
sampling technique, a case patient can also be a control patient, provided that the case patient
has not yet been diagnosed with NMSC (has not yet become a case) at the time he or she is
selected as a control. Once a case is diagnosed with NMSC, he or she is no longer eligible to
become a control. A total of 172 patients were included as both cases and controls. Each control
was assigned an index date whereby his or her corresponding length of observation time prior
to that date was equal to the observation time of the matched case prior to the diagnosis of
NMSC.
Assessment of exposures (medication use)—The primary medications evaluated
included: azathioprine and 6-mercaptopurine (thiopurine class), methotrexate, tacrolimus and
cyclosporine (calcineurin class), mycophenolate mofetil (MMF), infliximab and adalimumab
(biologic class). Corticosteroids were not included in our analysis due to varying indications
for use and varying length of therapy associated with each prescription. Medication exposures
were analyzed with respect to amount of time preceding the diagnosis of NMSC in cases, or
the corresponding index date in controls. “Recent” exposures were defined as at least one
outpatient pharmacy claim occurring in the 90 days prior to NMSC diagnosis. “Persistent” use
was defined as at least one outpatient pharmacy claim occurring in the 90 days prior to NMSC
diagnosis and at least one outpatient pharmacy claim occurring greater than 365 days prior to
NMSC diagnosis. Accordingly, persistent medication use was only assessed for those patients
whose NMSC (cases) or index date (controls) occurred >365 days from the beginning of the
follow up period.
Statistical analysis—Characteristics of cases and controls were described using the same
methods as in the cohort study. We then used conditional logistic regression to calculate odds
ratios (OR) and 95% confidence intervals for each medication exposure related to the outcome
of NMSC. We constructed a full model using all potential confounders and eliminated these
confounders via a backwards elimination strategy, using a change in estimate approach. The
only confounders of these associations were the other medication group (i.e. other
immunosuppressive medications were a confounder of the association between biologic anti-
TNF agents and NMSC, the inverse was also true). Analyses were performed for patients with
IBD and also stratified by UC and CD diagnosis. In the case of methotrexate use and biologic
use, these analyses were only performed for patients with CD. Methotrexate is not commonly
used in the treatment of UC in the United States and at the time these data were obtained, the
FDA had not yet approved infliximab for UC. Analyses of combined immunosuppression use
(immunomodulator and biologic) were also only performed in patients with CD.
For all analyses, p-values were two-sided, and a p-value of 0.05 or less was considered
statistically significant. All statistical analyses were performed using Stata version 9.0 (Texas
Station, TX). Analyses were performed for patients with IBD and also stratified by UC or CD
diagnosis. The study protocol was granted exemption from review by the Institutional Review




The study population for the cohort study included 53377 patients with IBD. Of these, 26403
had CD and 26974 had UC. The median length of follow-up within this cohort was 730 days
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(interquartile range 456–1004) for CD patients, 700 days (interquartile range 456–988) for UC
patients and 1004 days (interquartile range 730–1217) for controls. Characteristics of the
patients with IBD were well matched to their controls (Table 1).
For patients with IBD, the overall annual incidence rate of NMSC was 733 cases per 100,000.
The overall annual incidence rate of NMSC for controls was substantially lower (447 cases of
NMSC per 100,000). The incidence of NMSC for both patients with CD or UC, and their
matched controls, was highest in the South compared to other regions of the country
(Supplementary Figure 1). When IBD patients were compared to their matched controls, the
incidence rate ratio for NMSC was significantly higher for patients with IBD (IRR 1.64 95%
CI 1.51–1.78). The same was true when this was evaluated by disease sub-type (CD IRR 1.84,
95% CI 1.63–2.06, UC IRR 1.47, 95% CI 1.31–1.65). There were no important differences in
the incidence rate ratios by region (data not shown).
Nested Case-Control Study
The study population for the nested case-control study of IBD patients included 742 cases of
NMSC and 2968 matched controls. Age, gender, region, type of IBD, and time at risk did not
differ between cases and controls (Table 2). Differences in medication use are demonstrated
in Table 3. The cases had significantly greater recent use of thiopurines and recent use of any
non-biologic immunomodulator. For patients with CD, the cases also had greater recent use of
biologic anti-TNF agents.
In adjusted analyses, recent thiopurine use in particular (adjusted OR 3.56 95% CI 2.81–4.50)
and any recent immunosuppressive medication use (adjusted OR 3.28 95% CI 2.62–4.10) were
associated with NMSC. Among patients with CD, those who recently used biologic
medications also had increased odds of developing NMSC (adjusted OR 2.07 95% CI 1.28–
3.33) (Table 4). Patients with CD who recently used combined therapy (immunomodulator and
biologic) had increased odds of NMSC when compared to those using no medications (adjusted
OR 5.85 95% CI (3.2–10.8)) (Table 5).
We next analyzed persistent medication use in those patients with >365 days of follow-up prior
to their (or their matched case’s) diagnosis of NMSC. This population included 452 cases of
skin cancer and 1812 matched controls. Rates of persistent medication use by cases and controls
are demonstrated in Table 3. Again, cases had significantly greater thiopurine use and any
immunomodulator use. For those patients with CD, cases had greater biologic use when
compared to controls. In adjusted analyses, persistent thiopurine use (adjusted OR 4.27 95%
CI 3.08–5.92) and any persistent immunosuppressive medication use (adjusted OR 4.04 95%
CI 2.96–5.53) were associated with NMSC. Among patients with CD patients, persistent
biologic medication use was associated with NMSC (adjusted OR 2.18 95% CI 1.07–4.46)
(Table 4). Those who persistently used combined therapy (immunomodulator and biologic)
also had an increased odds of NMSC when compared to no medication use (adjusted OR 6.75
95% CI 2.74–16.65) (Table 5).
Discussion
This study demonstrates that inflammatory bowel disease patients have an increased risk of
NMSC (IRR 1.64 95% CI 1.51–1.78). This risk may be attributed, in part, to the underlying
immune dysfunction of IBD, although the use of immunosuppressive medications appears to
be a key driver as well. In particular, we observed that IBD patients with long term use of
thiopurines, other immunosuppressive agents, and patients with CD on anti-TNF medications
or a combination of anti-TNF and immunosuppressive medications appear to be at the highest
risk of developing NMSC. The findings presented in this study strongly suggest that NMSC
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can be considered a potential adverse effect of many IBD treatments, and should be considered
when weighing the risks and benefits of different therapeutic approaches.
A similar association between immunosuppressive use and NMSC in patients post solid-organ
transplant has also been demonstrated.16 Squamous cell and basal cell skin cancers account
for more than 90% of all skin cancers in post-transplant patients.6, 17 The risk of SCC is 65 to
250 times more common in transplant recipients than in the general population.6 Both duration
and level of immunosuppression have been positively associated with NMSC. Over 80% of
transplant recipients have developed SCC 20 years post transplant, demonstrating the
cumulative effects of long-term immunosupression.18 The magnitude of the association
between immunosuppressant use and NMSC observed in this study was less than that observed
in transplant recipients, perhaps related to lesser degrees of immunosuppression in IBD patients
and/or the exclusion of patients ≥ 64 years of age in our study.
Few previous studies have evaluated the risk of NMSC in patients with IBD. In a Danish study,
patients with UC were found to have an increased risk of NMSC (RR 1.4, 95% CI 1.0–1.9).7
A second Swedish study of patients with IBD demonstrated an increased risk of squamous cell
skin cancer (SIR 2.2 95% CI 1.1–3.9)8. Both of these studies did not have access to data on
medication exposures and were performed in Northern European populations, where skin type
and susceptibility to sun exposure may be different than that in the United States. Our study
also permitted further identification of risk factors for NMSC, including geographical region
(a proxy for sun exposure) and use of immunosuppressive medications.
Although immunosuppressive use in general has been previously associated with NMSC, to
our knowledge this is the first epidemiological study to describe an association between NMSC
and use of biologic therapies, specifically anti-TNF agents in patients with IBD. However, this
association has been suggested in case-reports of patients with rheumatoid arthritis (RA) treated
with biologic therapies.19 Additionally, a meta-analysis of the side-effects of anti-TNF agents
in the rheumatology population did find an overall increased risk of malignancy (pooled OR
3.3 (95% CI, 1.2–9.1)).20 Chakravarty et al demonstrated that patients with RA treated with
anti-TNF agents alone or in combination with methotrexate have an increased risk of NMSC.
21 In contrast to rheumatologic disease, anti-TNF medications have not previously been
associated with an increased risk of malignancy in patients with IBD.22,23 Until now, little was
known about the risk of NMSC in patients with IBD treated with anti-TNF agents or the
combination of anti-TNF agents and other immunosuppressive medications.
An interesting observation in our study was that the risk of NMSC seems to be greatest among
thiopurine (6MP/azathioprine) users. This finding is consistent with previous work
demonstrating that azathioprine can increase photosensitization of human skin.24 Patients
treated with azathioprine have a reduced minimal erythema dose (lowest amount of radiation
required to produce erythema 24 hours after irradiation) for UVA light, but not UVB light.
24 The selective sensitivity to UVA in azathioprine treated patients is consistent with the
production of 6-thioguanine DNA photoproducts. UVA light makes up a majority of incident
midday solar radiation, is able to penetrate through glass and is present throughout the year.
25 Therefore, many patients would be exposed to this harmful radiation inadvertently.
However, the carcinogenic effects of ultraviolet radiation are thought to be mostly caused by
UVB rather than UVA exposure.25 This underscores the need for further studies which
elucidate the biological mechanism responsible for this association.
The most significant strengths of this study include the large sample size and geographic
diversity of the study population, as well as the ability to assess both exposures and outcomes
in both the inpatient and outpatient settings. By drawing from a large number of health plans
of varying size, type, and location throughout the United States, we believe these results to be
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broadly generalizable. Another strength of this study was the ability to use pharmacy claims
to assess medication exposure, rather than relying on patient recall and/or medical records
which indicate medications prescribed (although not necessarily filled).
This study also has some limitations that merit consideration. First, as with all epidemiologic
studies using administrative data, there is always the possibility of misclassification of
exposure and outcome related to the lack of clinical detail. To minimize this risk, we used
stringent definitions of both exposures and outcomes. Similar previous administrative
definitions of IBD have been used by our group, 10, 11 and others.26 The administrative
definition of NMSC consisting of an ICD-9 diagnosis code in association with a pathology
CPT code has also been used previously.14 Due to overlapping ICD-9 codes, we were unable
to distinguish between basal cell and squamous cell skin cancers. Thus, the outcome was
classified as NMSC.
Another limitation to this study is that although our data source is generalizable to the
commercially insured population of the United States, the elderly and uninsured were not
represented in our population. To the extent that NMSC incidence increases with age, we may
have underestimated the overall incidence of this condition. However, this would not affect
the estimates of risk observed in our study, as measured by incidence rate ratios. Additionally,
our database did not contain data on race or ethnicity. Race could be an unmeasured confounder
if it is associated with both the outcome and the exposure. Race is associated with the outcome
of NMSC. Race may or may not be associated with our exposures of IBD (in the cohort study)
and immunosuppressive medication use (in the nested case-control study). Several studies
suggest that the incidence of IBD among African Americans is approaching that of Caucasians.
Among studies that have shown differences in immunosuppressive medication use by race,
27 many quote access to care and socioeconomic factors as a potential cause. In our study, all
patients are insured and have access to care, thereby alleviating many of the socioeconomic
factors.
A potential source of bias in the cohort portion of this study could be detection bias, either due
to increased health care contact by patients with IBD and/or lower thresholds for referral for
biopsy of suspicious skin lesions. The incidence rate of NMSC in our control group was 447
per 100,000. The incidence rate of NMSC in the US is in the range of 333–433 per 100,000.
Therefore, detection bias in the control group is likely relatively small. Additionally, we
included only insured patients, so access to care should be similar. Detection bias is less likely
to have occurred in the case-control study, as our IBD definition required both access to and
utilization of health care resources. A final limitation is that information regarding potential
confounders, such as smoking and sun exposure, are not available in administrative data.
However, our analysis was matched on region, as a proxy for sun exposure. Smoking alone is
unlikely to have caused the robust effect estimates observed in this study.
In summary, we have demonstrated an increased incidence of NMSC in patients with IBD, and
especially among those on immunosuppressive medications such as thiopurines and to a lesser
extent, patients with CD on anti-TNF medications. Given the increased use of these steroid-
sparing regimens by IBD patients and the potential for decades of exposure time, we anticipate
that the risks presented here will be magnified in years ahead. The findings in this study have
important implications for skin cancer screening and prevention. Although definitive
recommendations should be based not only on disease risk, but also on the benefits, harms,
and costs of screening and ultimate treatment, this study represents an important first step in
the development of prevention programs for patients with IBD. Such programs might include
behavior alterations such as sun avoidance and/or increased use of sun protective clothing and
broad spectrum sunscreen. Education for patients with IBD in regards to the increased risk of
NMSC associated with immunosuppressive medication use is also needed in order to change
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behaviors. Finally, there may also be a role for skin cancer screening programs, including full
skin examinations performed at regular intervals by trained dermatologists.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of the Study Population (Cohort Study): Patients with IBD and Controls matched by age (within
3 years), region of the country, and gender
CD (n=26403) UC (n=26974) Controls (n=160037)
Female gender (%) 14842 (56.2%) 14174 (52.6%) 87000 (54.4%)
Region of the country (%)
 East 6379 (24.2%) 6937 (25.7%) 39927 (25.0)
 Midwest 9462 (35.8%) 8949 (33.2%) 55189 (34.5)
 South 6243 (23.7%) 6044 (22.4%) 36840 (23.0)
 West 4319 (16.4%) 5044 (18.7%) 28081 (17.5)
Median time in cohort (days), (interquartile range) 730 (456–1004) 700 (456–988) 1004 (730–1217)
Mean age at cohort entry, (standard deviation) 39.1 (13.5) 41.5 (12.7) 39.7 (13.2)
Medicaid insurance (%) 621 (2.4%) 361 (1.3%) 3397 (2.1%)
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Table 2
Characteristics of the cases of NMSC with IBD and matched controls with IBD in nested case-control study,
matched by CD or UC, age (within 3 years), gender, and region of the country
Cases (n=742) Controls (n=2968)
Gender (n, %)
 Female n=353 47.6% n=1412 47.6%
 Male n=389 52.4% n=1556 52.4%
Mean age at IBD diagnosis (start of follow up), SD n=742 49.7 (8.7) n=2968 49.2 (9.4)
Median time at risk, days (interquartile range) n=742 483.5 (266–777) n=2968 483.5 (266–777)
IBD diagnosis
 CD, n (%) n=387 52.2% n=1548 52.2%
 UC, n (%) n=355 47.8% n=1420 47.8%
Region of the country
 East n=157 21.2% n=628 21.2%
 Midwest n=189 25.5% n=756 25.5%
 South n=253 34.1% n=1012 34.1%
 West n=143 19.3% n=572 19.3%
Medicaid (%) n=2 0.3% n=55 1.9%


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Long et al. Page 14
Table 5
Association of Recent and Persistent* Immunosuppressive Medication Combinations with Non-Melanoma Skin
Cancer Among Patients with Crohn’s Disease
Recent Use (≤90 days) Cases (n=387) Controls (n=1548) OR (95% CI)^ p value
None 250 (65%) 1331 (86%) 1.0 (reference)
Any immunomodulator** 101 (26%) 158 (10%) 3.71 (2.74–5.02) <0.001
Any biologic¶ 14 (4%) 36 (2%) 2.47 (1.29–4.73) 0.006
Combined immunomodulator and biologic 22 (6%) 23 (1%) 5.85 (3.2–10.8) <0.001
Persistent Use (> 365 days) Cases (n=228) Controls (n=913) OR (95% CI)^ p value
None 154 (68%) 817 (89%) 1.0 (reference)
Any immunomodulator** 56 (25%) 73 (8%) 4.45 (2.94–6.75) <0.001
Any biologic¶ 7 (3%) 13 (1%) 3.23 (1.24–8.45) 0.017
Combined immunomodulator and biologic 11 (5%) 10 (1%) 6.75 (2.74–16.65) <0.001
*
Only those with >365 days of exposure time prior to NMSC or index date were included in analyses of persistent medication use
^
ORs and 95% CI by multiple variable conditional logistic regression adjusting for Medicaid insurance status
**
Thiopurine class, calcineurin inhibitor, mycophenolate mofetil, methotrexate
¶
Adalimumab or infliximab
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